[en] Here we present pharmacological and clinical properties of a new fixed triple inhaled combination including an inhaled corticoid, a long acting ?2 agonist and a long acting anticholinergic for the treatment of severe chronic obstructive pulmonary disease (COPD). Trixeo Aerosphere® is the name of this triple combination which contains 160 µg budesonide, 4,8 µg formoterol and 9 µg glycopyrronium delivered by a pMDI. As compared to a budesonide/formoterol combination, Trixeo Aerosphere® improves forced expiratory volume in the first second (FEV1). As compared to glycopyrronium/formoterol combination, Trixeo Aerosphere® reduces exacerbation rate, improved quality of life and most importantly reduces mortality with a benefit increasing with blood eosinophil count. Trixeo Aerosphere® 320/18/9.6 is delivered twice daily 2 inhalations and is indicated in moderate to severe COPD insufficiently controlled by LABA/LAMA (long-acting ?2-adrenergic receptor agonist/ long-acting ?2-muscarinic receptor agonist) or ICS/LABA (inhaled corticosteroid/long-acting ?2-adrenergic receptor agonist).
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Louis, Renaud ; Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie
Bonhomme, Olivier ; Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie
HEINEN, Vincent ; Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie
NGUYEN DANG, Delphine ; Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie
VAN CAUWENBERGE, Hélène ; Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie
Corhay, Jean-Louis ; Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie
Language :
French
Title :
Le médicament du mois. Combinaison fixe budésonide, formotérol, glycopyronium pour le traitement de la BPCO modérée à sévère : Trixeo Aerosphère®.
Alternative titles :
[en] Fixed combination of budesonide, formoterol, glycopyrronium for the treatment of severe COPD : Trixeo Aerosphere®.
Publication date :
April 2022
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Be